VEB.RF Finances Development of One More Drug to Treat Severe Coronavirus Cases
VEB.RF provided financing to R-Pharm for the development of another drug (RPH-104) to treat severe COVID-19 cases. The clinical trials are ongoing. The news was announced by VEB.RF’s First Deputy Chairman and Member of the Management Board Nikolay Tsekhomsky in an interview with Russian News Agency TASS.
“The clinical trials are ongoing to test the effectiveness of another drug (RPH-104) from R-Pharm’s portfolio for treatment of severe COVID-19 cases. VEB.RF has financed the project,” Nikolay Tsekhomsky said.
As previously announced, VEB.RF invested 9.4 billion roubles into R-Pharm’s Artlegia (olokizumab) drug development for treatment of severe and complicated coronavirus cases. The Russian Ministry of Health included the drug to its new coronavirus treatment guidelines.
The Zvezda shipyard has launched the construction of a Sovcomflot commissioned Aframax tanker with financial support from VEB.RF.
In September 2018, Rosneft, Zvezda, Arctic Leasing and SCF ECO (a Sovcomflot’s subsidiary) entered into an agreement to build two oil tankers for subsequent long-term chartering. The handover of the first tanker to the customer is planned for 2022.
“VEB.RF Group is a financial partner for the Zvezda shipyard to build two Aframax tankers commissioned by Sovcomflot. We opened financing for this project in June 2019. The construction of the tankers produces a multiplying effect on the economy of the Far East and the national economy in general. It is important for us to support such projects, as they secure the development of the economy for several years ahead by creating jobs, state-of-the-art infrastructure, and additional tax proceeds. VEB.RF’s governing bodies approved participation in the financing of 21 tankers, and Zvezda has launched the construction of one Aframax tanker and one shuttle tanker,” VEB.RF Chairman Igor Shuvalov said.